RNS Number : 2889K
Futura Medical PLC
31 October 2024

31 October 2024

Futura Medical plc

("Futura", "the Group" or the "Company")

Total Voting Rights

Futura Medical plc (AIM: FUM), the consumer healthcare company behind Eroxon®, that specialises in the development and global commercialisation of innovative and clinically proven sexual health products, announces that for the purposes of the FCA's Disclosure and Transparency Rules, the Company's total issued share capital at the date of this announcement is 303,703,568 Ordinary Shares.

Since the Company currently holds no shares in treasury, the total number of voting rights in the Company is 303,703,568 and this figure may therefore be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

Contacts:

Futura Medical plc	James Barder *Chief Executive Officer* Angela Hildreth *Finance Director and COO*	investor.relations@futuramedical.com +44 (0)1483 685 670 www.futuramedical.com
Panmure Liberum Nominated Adviser and Broker	Emma Earl, Will Goode, Mark Rogers (Corporate Finance) Rupert Dearden (Corporate Broking)	+44 (0)20 3100 2000
Stifel Nicolaus Europe Limited Joint Broker	Alan Selby Ben Maddison	+44 (0)207 710 7600
Alma Strategic Communications	Rebecca Sanders-Hewett Sam Modlin Will Ellis Hancock	+44 (0)20 3405 0205 futura@almastrategic.com

Notes to Editors:

Futura Medical plc (AIM: FUM) is the developer of innovative sexual health products, including lead product Eroxon. Our core strength lies in our research, development and commercialisation of topically delivered gel formulations in sexual health products.

Eroxon, Futura's clinically proven lead product, has been developed for the treatment of Erectile Dysfunction ("ED"). The highly differentiated product, which is the only topical gel treatment for ED available over the counter and helps men get an erection in ten minutes, addresses significant unmet needs in the ED market.

ED impacts 1 in 5 men globally across all adult age brackets, with approximately half of all men over 40 experiencing ED and 25% of all new diagnoses being in men under 40.

Futura has distribution partners in place in a number of major consumer markets including Haleon in the US, the largest market for ED in the world, and Cooper Consumer Health in Europe. Eroxon has been nominated for a number of healthcare industry awards and has won two to-date.

END

TVRZZMFGVGRGDZM